Charles River Laboratorie... (CRL)
NYSE: CRL
· Real-Time Price · USD
138.65
-0.30 (-0.22%)
At close: May 15, 2025, 3:59 PM
138.89
0.17%
After-hours: May 15, 2025, 06:00 PM EDT
Charles River Laboratories International Revenue Breakdown
| Period Ending | Dec 28, 2024 | Dec 30, 2023 | Dec 31, 2022 | Dec 25, 2021 | Dec 26, 2020 | Dec 28, 2019 | Dec 29, 2018 | Dec 30, 2017 | Dec 31, 2016 | Dec 26, 2015 | Dec 27, 2014 | Dec 28, 2013 | Dec 29, 2012 | Dec 31, 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Discovery and Safety Assessment Revenue | 2.45B | 2.62B | 2.45B | 2.11B | 1.84B | 1.62B | 1.32B | 980.02M | 836.59M | 612.17M | 538.22M | 594.21M | 601.46M | 580.14M |
| Discovery and Safety Assessment Revenue Growth | -6.28% | +6.88% | +16.14% | +14.68% | +13.49% | +22.94% | +34.37% | +17.14% | +36.66% | +13.74% | -9.42% | -1.21% | +3.68% | n/a |
| Manufacturing Support Revenue | 769.33M | 721.44M | 789.57M | 742.49M | 515.35M | 465.14M | 429.56M | 383.96M | 350.8M | 277.9M | 372.03M | n/a | n/a | n/a |
| Manufacturing Support Revenue Growth | +6.64% | -8.63% | +6.34% | +44.07% | +10.79% | +8.28% | +11.88% | +9.45% | +26.23% | -25.30% | n/a | n/a | n/a | n/a |
| Research Models and Services Revenue | 829.38M | 792.34M | 739.17M | 690.44M | 571.15M | 537.09M | 519.68M | 493.62M | 494.04M | 473.23M | 507.33M | n/a | n/a | n/a |
| Research Models and Services Revenue Growth | +4.67% | +7.19% | +7.06% | +20.88% | +6.34% | +3.35% | +5.28% | -0.09% | +4.40% | -6.72% | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 29, 2025 | Dec 28, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 30, 2023 | Sep 30, 2023 | Jul 1, 2023 | Apr 1, 2023 | Dec 31, 2022 | Sep 24, 2022 | Jun 25, 2022 | Mar 26, 2022 | Dec 25, 2021 | Sep 25, 2021 | Jun 26, 2021 | Mar 27, 2021 | Dec 26, 2020 | Sep 26, 2020 | Jun 27, 2020 | Mar 28, 2020 | Dec 28, 2019 | Sep 28, 2019 | Jun 29, 2019 | Mar 30, 2019 | Dec 29, 2018 | Sep 29, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 30, 2017 | Sep 30, 2017 | Jul 1, 2017 | Apr 1, 2017 | Dec 31, 2016 | Sep 24, 2016 | Jun 25, 2016 | Mar 26, 2016 | Dec 26, 2015 | Sep 26, 2015 | Jun 27, 2015 | Mar 28, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 177.8M | 195.71M | 199.21M | 165.85M | 177.22M | 197.14M | 176.11M | 199.76M | 173.71M | 199.64M | 183.71M | 129.78M | 150.03M | 144.11M | 148.57M | 171.5M | 155.73M | 143.03M | 128.29M | 127.71M | 129.9M | 129.6M | 129.51M | 135.94M | 122.57M | 106.92M | 113.03M | 120.53M | 103.37M | 94.56M | 92.86M | 94.53M | 91.49M | 98.48M | 85.65M | 100.47M | 82.94M | 81.46M | 76.22M | 71.33M | 71.4M |
| Selling, General, and Administrative Revenue Growth | -9.15% | -1.76% | +20.11% | -6.41% | -10.11% | +11.94% | -11.84% | +15.00% | -12.99% | +8.67% | +41.56% | -13.50% | +4.11% | -3.00% | -13.37% | +10.13% | +8.88% | +11.49% | +0.45% | -1.69% | +0.23% | +0.07% | -4.73% | +10.91% | +14.64% | -5.41% | -6.22% | +16.60% | +9.32% | +1.83% | -1.77% | +3.33% | -7.10% | +14.98% | -14.75% | +21.13% | +1.82% | +6.87% | +6.86% | -0.09% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |